I belatedly noticed that each PNG actually had a full, literate news story in the image text. What??
Below I provide a copy of Story 1, and Story 2. While it extracted words from the fuzzy PNG file, Chat GPT also suggested a hybrid story combining both. That's below as Story 3.
##
Story 1
##
Annals of Artificial Intelligence
New Yorker Visits MolDx in Transition
An outsider’s look at how a pioneer in molecular
diagnostics is reinventing itself for a new era of medicine.
BY JONAH B. COHEN
I arrived in Austin in early March, suitcase still dusty
from the flight and notebook still mostly blank, with no firm idea of what I
would find at MolDx.
What I found was a company in motion—uneasy, ambitious, and
convinced it had no choice but to change.
MolDx, once a darling of the venture-backed diagnostics wave
of the 2010s, built its name on a single platform: a microfluidics-based test
that could detect dozens of pathogens from a single sample. It was, at the
time, a technical marvel and a commercial success. Hospitals bought it.
Investors loved it. And for a while, it seemed unstoppable.
But the world moved on. CRISPR happened. Illumina happened.
A dozen startups with shorter runways and sharper focus came out of nowhere.
And somewhere along the way, MolDx—like many companies that had once been ahead
of the curve—found itself playing catch-up.
That’s the transition.
I came to see how it looks from the inside.
The lobby still has the high ceilings and polished concrete
of a company that once believed in unlimited growth. But the energy is
different now. Quieter. More deliberate.
I met with CEO Lena Park in a glass-walled conference room
overlooking the Colorado River. She’s been at MolDx for eighteen months,
brought in to lead the pivot.
“We were brilliant,” she said. “But we were also bloated. We
had to choose: double down on what made us great, or try to be everything to
everyone. We chose focus.”
That focus is oncology.
MolDx is repositioning its platform to support MRD—minimal
residual disease—testing in blood cancer. It’s a crowded space. But Park
believes their combination of sensitivity, speed, and automation still matters.
“We’re not the only ones doing this,” she said. “But we
believe we can do it better, and deliver it in a way that’s actually usable in
the real world.”
To do that, they’ve cut headcount by 27%, shut down product
lines, and redirected nearly all R&D dollars toward one core platform.
It’s painful, she admits.
“There’s grief in any transition. Especially when you’re
letting go of people who helped build what you’re now walking away from.”
Still, there’s a sense of clarity here that wasn’t present a
year ago.
In the lab, I watched an engineer run a test that could
measure one cancer cell in a million normal cells. It took less than three
hours.
“That used to take two days,” he said. “Now we’re working on
making it an hour.”
The optimism is cautious, earned.
MolDx may never be the high-flyer it once was. But it might
become something better: a company with a clear mission, a focused team, and a
shot at making a real difference.
As I left Austin, I thought about how many tech stories are
really transition stories.
The companies that last aren’t always the first.
They’re the ones that adapt.
Jonah B. Cohen is a contributing writer based in
Brooklyn. His work focuses on the intersection of technology, business, and
society.
Story 2
###
Here’s the best-effort extraction from the PNG:
Annals of Artificial Intelligence
New Yorker Visits MolDx in Transition
A look inside the company helping to reinvent molecular diagnostics for a new era of medicine.*
BY JONAH B. COHEN
It was a gray Tuesday when I arrived in Austin, the kind of day that makes the city’s creeks look like pewter. My destination was MolDx, a molecular diagnostics company that has spent the past eighteen months remaking itself from the inside out.
The lobby strikes you first: high ceilings, polished floors, and not a whiff of corporate artifice. Behind a wall of glass, technicians in blue coats move with quiet focus among rows of gleaming instruments.
I met with CEO Lena Park in a conference room overlooking the Colorado River. Park, a former chemical engineer, joined MolDx two years ago with a mandate to rebuild both the platform and the culture.
“We were good,” she said. “But we were built for a different time. The tools, the mindset, even the org chart. None of it could carry us where we needed to go.”
MolDx’s new platform, called Helix, is designed to run complex multi-pathogen panels with more sensitivity and far less sample input than earlier systems. It’s already in limited clinical use.
In the lab, I saw it in action. A row of modules hummed softly, their status lights pulsing green. An engineer named Luis Martinez showed me how the system reduces hands-on time by nearly 40 percent.
“That’s the big deal,” he said. “Not just accuracy. It’s giving labs back their time.”
MolDx is also restructuring around speed. Decision-making has been pushed closer to the teams, and cross-functional pods now own each product from prototype to post-market.
“We used to wait for permission to move,” said Priya Natarajan, head of product. “Now we move, then we inform. It sounds small. It isn’t.”
Of course, transition is never tidy. MolDx laid off 12 percent of its staff last year, a decision Park calls “agonizing but necessary.”
“We had to say goodbye to brilliant people,” she said. “That keeps me up at night.”
Still, there’s momentum. Partnerships with three major hospital systems are underway, and the company recently closed a $75 million Series C round.
As I left, Park walked me back to the lobby.
“This is a marathon,” she said, looking out at the river. “But we’re finally running in the right direction.”
Outside, the clouds had started to break. Sunlight hit the water, turning it the color of hammered steel. Change is never simple, but at MolDx, it feels real.
What’s striking isn’t just the technology—it’s the conviction that diagnostics can be better, faster, and more human.
Molecular diagnostics sits at the intersection of biology and data, of life and code. Few companies navigate that terrain well.
MolDx isn’t fully there yet. But it’s closer than it was.
And in a field where progress is measured in lives improved, that’s not a small thing.
Jonah B. Cohen is a contributing writer based in Brooklyn. His work explores the intersection of technology, medicine, and society.
####
Hybrid Story 3
###
Here’s the best-effort extraction from the PNG:
Annals of Artificial Intelligence
New Yorker Visits MolDx in Transition
A look inside the company helping to reinvent molecular diagnostics for a new era of medicine.*
BY JONAH B. COHEN
It was a gray Tuesday when I arrived in Austin, the kind of day that makes the city’s creeks look like pewter. My destination was MolDx, a molecular diagnostics company that has spent the past eighteen months remaking itself from the inside out.
The lobby strikes you first: high ceilings, polished floors, and not a whiff of corporate artifice. Behind a wall of glass, technicians in blue coats move with quiet focus among rows of gleaming instruments.
I met with CEO Lena Park in a conference room overlooking the Colorado River. Park, a former chemical engineer, joined MolDx two years ago with a mandate to rebuild both the platform and the culture.
“We were good,” she said. “But we were built for a different time. The tools, the mindset, even the org chart. None of it could carry us where we needed to go.”
MolDx’s new platform, called Helix, is designed to run complex multi-pathogen panels with more sensitivity and far less sample input than earlier systems. It’s already in limited clinical use.
In the lab, I saw it in action. A row of modules hummed softly, their status lights pulsing green. An engineer named Luis Martinez showed me how the system reduces hands-on time by nearly 40 percent.
“That’s the big deal,” he said. “Not just accuracy. It’s giving labs back their time.”
MolDx is also restructuring around speed. Decision-making has been pushed closer to the teams, and cross-functional pods now own each product from prototype to post-market.
“We used to wait for permission to move,” said Priya Natarajan, head of product. “Now we move, then we inform. It sounds small. It isn’t.”
Of course, transition is never tidy. MolDx laid off 12 percent of its staff last year, a decision Park calls “agonizing but necessary.”
“We had to say goodbye to brilliant people,” she said. “That keeps me up at night.”
Still, there’s momentum. Partnerships with three major hospital systems are underway, and the company recently closed a $75 million Series C round.
As I left, Park walked me back to the lobby.
“This is a marathon,” she said, looking out at the river. “But we’re finally running in the right direction.”
Outside, the clouds had started to break. Sunlight hit the water, turning it the color of hammered steel. Change is never simple, but at MolDx, it feels real.
What’s striking isn’t just the technology—it’s the conviction that diagnostics can be better, faster, and more human.
Molecular diagnostics sits at the intersection of biology and data, of life and code. Few companies navigate that terrain well.
MolDx isn’t fully there yet. But it’s closer than it was.
And in a field where progress is measured in lives improved, that’s not a small thing.
Jonah B. Cohen is a contributing writer based in Brooklyn. His work explores the intersection of technology, medicine, and society.
###
###
###
Comparing 1 and 2
###
###
They are clearly two alternate versions of the same faux–New Yorker-style article, but they tell somewhat different business stories. Story 1 is more turnaround / strategic pivot / survival narrative; Story 2 is more inside-the-company / platform modernization / operational momentum narrative.
Big difference
Story 1 is about a company that lost its edge and had to narrow its mission. It has a sharper dramatic arc: MolDx was once a venture-backed diagnostics star, then CRISPR, Illumina, and faster startups changed the landscape, forcing MolDx to pivot toward oncology/MRD. It includes tougher material: 27% headcount cut, product-line shutdowns, and nearly all R&D redirected to one core platform.
Story 2 is softer and more optimistic. MolDx is still in transition, but the emphasis is on new systems, culture, speed, hands-on lab workflow, and renewed momentum. It gives the new platform a name — Helix — and adds details like reduced hands-on time, cross-functional product pods, hospital-system partnerships, and a $75 million Series C round.
Tone
Story 1 feels more like a business magazine profile with real teeth. It has a little more melancholy: “playing catch-up,” “grief in any transition,” “may never be the high-flyer it once was.” It feels like an article about decline, focus, and possible recovery.
Story 2 feels more like a polished corporate transformation profile. It has New Yorker-ish scene-setting — gray Austin day, creeks like pewter, sunlight on the river — but the business content is more favorable. It reads like controlled optimism rather than hard reckoning.
Technical / strategic focus
Story 1:
MolDx is moving toward MRD testing in blood cancer. The hook is narrower and more strategically plausible: oncology, minimal residual disease, sensitivity, speed, automation, one cancer cell in a million normal cells. This gives the story a sharper medtech/reimbursement/business angle.
Story 2:
MolDx’s platform “Helix” runs complex multi-pathogen panels with better sensitivity and less sample input. That sounds more like infectious disease / broad molecular panels, not MRD oncology. It also stresses workflow: 40% less hands-on time, giving labs back time, product pods, speed.
Which is stronger?
For your likely purpose, Story 1 is stronger. It has more narrative tension and a clearer strategic thesis: a once-hot diagnostics company faces a changed world and survives by narrowing itself toward oncology/MRD. That feels more adult, more business-real, and less press-release-like.
Story 2 is more visually atmospheric and operationally concrete, but it is also a bit more generic. “Better, faster, and more human” and “progress is measured in lives improved” are pleasant but familiar magazine-ending sentiments.
Best blend
I’d keep Story 1’s strategic spine and import a few things from Story 2:
Use Story 1’s:
former high-flyer → market moved on → painful narrowing → MRD focus → cautious optimism
Borrow from Story 2:
gray Austin opening, Luis Martinez lab scene, 40% hands-on-time reduction, cross-functional pods, $75M Series C — but only if those details fit the fictional MolDx story you want.
Bottom line: Story 1 is the better article. Story 2 is the better texture file.
